SensoGenic: empower food allergy sufferers and their families with the freedom to enjoy eating safely everywhere & anytime

Project Information

SensoGenic

Grant agreement ID: 867865

DOI

10.3030/867865

Project closed

EC signature date 23 April 2019

Start date 1 March 2019

End date 31 August 2019

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

SENSOGENIC LTD
Israel

Periodic Reporting for period 1 - SensoGenic (SensoGenic: empower food allergy sufferers and their families with the freedom to enjoy eating safely everywhere & anytime)

Reporting period: 2019-03-01 to 2019-08-31

Summary of the context and overall objectives of the project

The global allergy epidemic is an ever-present growing problem: food allergy cases have risen by as much as 50% in the past decade, and this trend does not seem to be slowing . Food allergies are classified as an immune response to a substance of a particular nature that an individual is hypersensitive to. These responses can be anywhere from quite mild, slight rashes or stuffy noses, to severe anaphylaxis requiring immediate hospitalization.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

SensoGenic Ltd. is a science and technology company based in Israel, that is developing a food allergens biosensor which is a portable, handheld, digital diagnostic analyser. Currently, there are no consumer solutions in the market that address food allergens detection. The solutions for food manufactures include very laborious, time and resource consuming, and expensive laboratory tests. SensoGenic focuses on a consumer product which detects peanuts and eggs simultaneously in relevant food and concentrations. After successfully validating SensoGenic's POC we can confirm the capability of our breakthrough IP as a unique approach for allergen protein detection.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

As part of this feasibility study, SensoGenic held discussions with leading food and beverage manufacturers and KOLs in the specialist medical community associated with treating food allergies. These discussions, as well as requests received via our website from parents of children suffering from food allergies, have confirmed the need for a device that can detect food allergens as a means to improve the quality of life of food allergy sufferers and reduce emergency medical incidents as a direct result of food allergy.

Furthermore, this feasibility study aimed to improve SensoGenic's understanding of international market conditions and the associated risks that need to be considered as the company develops a deeper business plan for rolling out and scaling up SensoGenic as a marketable innovative solution. We succeeded in achieving this goal by conducting market research, discussions with key players in applicable markets, and building an initial business plan and go to market strategy. The conclusion of the study is that this SenoGenic project is a viable, worthwhile project to pursue that has potential for immense economic and social impact for food allergy sufferers.

SensoGenic at different events